Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2366-2370

  Bodmer, Michael ^a   Amico, Patrizia ^a   Mihatsch, Michael J ^a   Haschke, Manuel ^a   Kummer, Oliver ^a   Krähenbühl, Stephan ^a   Mayr, Michael ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Bisphosphonates; Collapsing glomerulopathy; Focal segmental glomerulosclerosis; Pamidronate; Renal failure; Zoledronate

Indexed keywords

AMLODIPINE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; AGED; ANAMNESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW CELL; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; CAUCASIAN; DRUG DOSE REDUCTION; GLOMERULOSCLEROSIS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; LONG TERM CARE; MALE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; PRIORITY JOURNAL;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMIDAZOLES; KIDNEY; MALE; MULTIPLE MYELOMA; NEPHROTIC SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 34547851708     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm209     Document Type: Article

References (26)

1. Russell RG, Bisaz S, Fleisch H et al. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 1970; 2: 899-902
2. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17: 897-907
3. Lehenkari PP, Kellinsalmi M, Napankangas JP et al. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002; 61: 1255-1262
4. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589
5. Kavanagh KL, Guo K, Dunford SE et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 2006; 103: 7829-7834
6. Hosfield DJ, Zhang Y, Dougan DR et al. Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis. J Biol Chem 2004; 279: 8526-8529
7. Chen T, Berenson J, Vescio R et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42: 1228-1236
8. Major PP, Coleman RE. Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program. Semin Oncol 2001; 28: 17-24
9. Markowitz GS, Fine PL, Stack JI et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-289
10. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387
11. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-1200
12. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med 2003; 349
13. Tanvetyanon T, Choudhury AM. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother 2004; 38: 418-421
14. Jones SG, Dolan G, Lengyel K, Myers B. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions. Br J Haematol 2002; 119: 576-577
15. Munier A, Gras V, Andrejak M et al. Zoledronic Acid and renal-toxicity: Data from French adverse effect reporting database. Ann Pharmacother 2005, 39: 1194-1197
16. Kunin M, Kopolovic J, Avigdor A, Holtzman EJ. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant 2004; 19: 723-726
17. Barri YM, Munshi NC, Sukumalchantra S et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65: 644-641
18. Markowitz GS, Fine PL, D'Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002; 39: 1118-1122
19. Markowitz GS, Appel GB, Fine PL et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12: 1164-1172
20. Meyrier A. Mechanisms of disease: Focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 2005; 1: 44-54
21. D'Agati V, Suh JI, Carbone L, Cheng JT, Appel G. Pathology of HIV-associated nephropathy: A detailed morphologic and comparative study. Kidney Int 1989; 35: 1358-1370
22. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: A novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 1999; 10: 51-61
23. Moudgil A, Nast CC, Bagga A et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001; 59: 2126-2133
24. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: A working proposal. Am J Kidney Dis 2004; 43: 368-382
25. Schiffer M, Haller H. Focal segmental glomerulosclerosis (FSGS). Molecular defects and clinical relevance. Dtsch Med Wochenschr 2006; 131: 1541-1545
26. Daskalakis N, Winn MP. Focal and, segmental glomerulosclerosis. Cell Mol Life Sci 2006; 63: 2506-2511